AARTI PHARMALABS Financial Statement Analysis
|
||
|
The Revenues of AARTI PHARMALABS have decreased by -4.76% YoY .
The Earnings Per Share (EPS) of AARTI PHARMALABS has increased by 25.62 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AARTI PHARMALABS Last 5 Annual Financial Results
[BOM: 543748|NSE : AARTIPHARM]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,853 Cr | ₹1,945 Cr | ₹1,200 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Expenses | ₹1,467 Cr | ₹1,603 Cr | ₹995 Cr | ₹0.01 Cr | ₹0.01 Cr |
| Operating Profit (Excl OI) | ₹386 Cr | ₹342 Cr | ₹205 Cr | ₹-0.01 Cr | ₹-0.01 Cr |
| Other Income | ₹4.90 Cr | ₹2.32 Cr | ₹4.19 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Interest | ₹17 Cr | ₹21 Cr | ₹12 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Depreciation | ₹73 Cr | ₹63 Cr | ₹42 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Profit Before Tax | ₹300 Cr | ₹261 Cr | ₹155 Cr | ₹-0.01 Cr | ₹-0.01 Cr |
| Profit After Tax | ₹217 Cr | ₹193 Cr | ₹122 Cr | ₹-0.01 Cr | ₹-0.01 Cr |
| Consolidated Net Profit | ₹217 Cr | ₹193 Cr | ₹122 Cr | ₹-0.01 Cr | ₹-0.01 Cr |
| Earnings Per Share (Rs) | ₹30.06 | ₹23.93 | ₹21.35 | ₹4,890.04 | ₹-0.18 |
| PAT Margin (%) | 12.88 | 11.71 | 9.95 | 10.19 | 0.00 |
| ROE(%) | 14.55 | 13.08 | 13.35 | 18.23 | -2.02 |
| ROCE(%) | 17.59 | 16.75 | 16.11 | 19.40 | -1.87 |
| Total Debt/Equity(x) | 0.20 | 0.15 | 0.14 | 0.25 | 0.08 |
Key Financials |
||
| Market Cap | : | ₹ 6,839.4 Cr |
| Revenue (TTM) | : | ₹ 1,906.1 Cr |
| Net Profit(TTM) | : | ₹ 242.2 Cr |
| EPS (TTM) | : | ₹ 26.7 |
| P/E (TTM) | : | 28.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AARTI PHARMALABS | 2.4% | 0.9% | 15.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | -3.9% | -5.8% |
| DIVIS LABORATORIES | -2.3% | 0.9% | 12.9% |
| CIPLA | -4.2% | -3.1% | -1.9% |
| TORRENT PHARMACEUTICALS | 0.3% | 3.9% | 19.2% |
| DR REDDYS LABORATORIES | -3.2% | -4.5% | -11.8% |
| MANKIND PHARMA | -0.7% | 2.8% | -23.5% |
| ZYDUS LIFESCIENCES | -3.9% | -3% | -8.8% |
| LUPIN | 1.8% | 5.3% | -3.2% |
AARTI PHARMALABS Revenues
[BOM: 543748|NSE : AARTIPHARM]
| Y-o-Y | -4.76 % |
| 5 Yr CAGR | 0 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,853 Cr | -4.76 | |
| Mar2024 | ₹1,945 Cr | 62.11 | |
| Mar2023 | ₹1,200 Cr | 0 | |
| Mar2022 | ₹0.00 Cr | 0 | |
| Mar2021 | ₹0.00 Cr | - | |
AARTI PHARMALABS Operating Profit
[BOM: 543748|NSE : AARTIPHARM]
| Y-o-Y | 12.86 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹386 Cr | 12.86 | |
| Mar2024 | ₹342 Cr | 66.64 | |
| Mar2023 | ₹205 Cr | Positive | |
| Mar2022 | ₹-0.01 Cr | Negative | |
| Mar2021 | ₹-0.01 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 18.54 % |
| 5 Yr CAGR | 0 |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 20.84% | 18.54 | |
| Mar2024 | 17.58% | 2.75 | |
| Mar2023 | 17.11% | 0 | |
| Mar2022 | 0% | 0 | |
| Mar2021 | 0% | - | |
AARTI PHARMALABS Profit After Tax
[BOM: 543748|NSE : AARTIPHARM]
| Y-o-Y | 12.10 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹217 Cr | 12.10 | |
| Mar2024 | ₹193 Cr | 58.28 | |
| Mar2023 | ₹122 Cr | Positive | |
| Mar2022 | ₹-0.01 Cr | Negative | |
| Mar2021 | ₹-0.01 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 9.99 % |
| 5 Yr CAGR | 0 |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 12.88 % | 9.99 | |
| Mar2024 | 11.71 % | 17.69 | |
| Mar2023 | 9.95 % | -2.36 | |
| Mar2022 | 10.19 % | 0 | |
| Mar2021 | 0 % | - | |
AARTI PHARMALABS Earnings Per Share (EPS)
[BOM: 543748|NSE : AARTIPHARM]
| Y-o-Y | 25.62 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹30 | 25.62 | |
| Mar2024 | ₹24 | 12.08 | |
| Mar2023 | ₹21 | -99.56 | |
| Mar2022 | ₹4,890 | Positive | |
| Mar2021 | ₹-0.18 | - | |
AARTI PHARMALABS Return on Capital Employed (ROCE)
[BOM: 543748|NSE : AARTIPHARM]
| Y-o-Y | 5.01 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 17.59% | 5.01 | |
| Mar2024 | 16.75% | 3.97 | |
| Mar2023 | 16.11% | -16.96 | |
| Mar2022 | 19.4% | Positive | |
| Mar2021 | -1.87% | - | |
AARTI PHARMALABS Share Price vs Sensex
| Current Share Price | : | ₹754.9 |
| Current MarketCap | : | ₹ 6,839.4 Cr |
| Updated EOD on | : | Jan 12,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI PHARMALABS | 2.4% |
0.9% |
15.8% |
| SENSEX | -1.8% |
-0.6% |
7.3% |
AARTI PHARMALABS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | -1.2% | -0.5% | -4.5% |
| BSE SMALLCAP | -4.6% | -1.5% | -10.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | -2.4% | 0.3% | 4.5% |
| NIFTY MICROCAP 250 | -5.1% | -2.3% | -13.6% |
You may also like the below Video Courses
FAQ about AARTI PHARMALABS Financials
How the annual revenues of AARTI PHARMALABS have changed ?
The Revenues of AARTI PHARMALABS have decreased by -4.76% YoY .
How the Earnings per Share (EPS) of AARTI PHARMALABS have changed?
The Earnings Per Share (EPS) of AARTI PHARMALABS has increased by 25.62 % YoY .
Check out Intrinsic Value of Peers of AARTI PHARMALABS
Compare Stock Analytics of Peers of AARTI PHARMALABS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
